| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,281,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Co.'s primary product candidate, efruxifermin, is an analog of fibroblast growth factor 21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
200,000 |
800,000 |
1,200,000 |
| Total Buy Value |
$0 |
$3,677,505 |
$22,531,214 |
$32,931,214 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
8 |
9 |
| Total Shares Sold |
110,332 |
176,617 |
519,059 |
3,046,073 |
| Total Sell Value |
$3,553,208 |
$4,744,191 |
$22,222,916 |
$129,158,693 |
| Total People Sold |
5 |
5 |
7 |
9 |
| Total Sell Transactions |
9 |
19 |
44 |
86 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  White William Richard |
Chief Financial Officer |
• – – |
2023-06-13 |
4 |
AS |
$55.16 |
$33,427 |
D/D |
(606) |
22,377 |
|
- |
|
| Cheng Andrew |
President and CEO |
• • – |
2023-06-01 |
4 |
AS |
$44.18 |
$1,127,430 |
D/D |
(25,000) |
409,293 |
|
- |
|
| Cheng Andrew |
President and CEO |
• • – |
2023-06-01 |
4 |
OE |
$0.62 |
$36,459 |
D/D |
25,000 |
434,293 |
|
- |
|
| Graham G. Walmsley |
|
– • – |
2023-05-19 |
4 |
B |
$42.00 |
$5,040,000 |
I/I |
120,000 |
520,000 |
0.01 |
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-05-01 |
4 |
AS |
$45.00 |
$1,126,860 |
D/D |
(25,000) |
409,293 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-05-01 |
4 |
OE |
$0.62 |
$15,375 |
D/D |
25,000 |
434,293 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-04-18 |
4 |
OE |
$0.62 |
$24,600 |
D/D |
40,000 |
409,293 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-04-03 |
4 |
AS |
$37.88 |
$948,576 |
D/D |
(25,000) |
369,293 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-04-03 |
4 |
OE |
$0.62 |
$15,375 |
D/D |
25,000 |
394,293 |
|
- |
|
| White William Richard |
Chief Financial Officer |
• – – |
2023-03-10 |
4 |
D |
$43.47 |
$27,864 |
D/D |
(641) |
22,983 |
|
- |
|
| Yale Catriona |
Chief Development Officer |
• – – |
2023-03-10 |
4 |
D |
$43.46 |
$30,465 |
D/D |
(701) |
80,567 |
|
- |
|
| Rolph Timothy |
Chief Scientific Officer |
• – – |
2023-03-10 |
4 |
D |
$43.47 |
$26,212 |
D/D |
(603) |
189,929 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-03-10 |
4 |
D |
$43.47 |
$74,160 |
D/D |
(1,706) |
369,293 |
|
- |
|
| Young Jonathan |
Chief Operating Officer |
• – – |
2023-03-10 |
4 |
D |
$43.47 |
$27,560 |
D/D |
(634) |
184,277 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-03-01 |
4 |
AS |
$45.54 |
$1,166,338 |
D/D |
(25,000) |
370,999 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-03-01 |
4 |
OE |
$0.62 |
$15,375 |
D/D |
25,000 |
395,999 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-02-01 |
4 |
AS |
$48.57 |
$1,226,395 |
D/D |
(25,000) |
370,999 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-02-01 |
4 |
OE |
$0.62 |
$15,375 |
D/D |
25,000 |
395,999 |
|
- |
|
| Yale Catriona |
Chief Development Officer |
• – – |
2023-01-13 |
4 |
AS |
$49.12 |
$252,651 |
D/D |
(5,000) |
81,268 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-01-03 |
4 |
AS |
$50.12 |
$1,281,751 |
D/D |
(25,000) |
370,999 |
|
- |
|
| Cheng Andrew |
President & CEO |
• • – |
2023-01-03 |
4 |
OE |
$0.62 |
$15,375 |
D/D |
25,000 |
395,999 |
|
- |
|
| Young Jonathan |
Chief Operating Officer |
• – – |
2023-01-03 |
4 |
AS |
$54.64 |
$479,560 |
D/D |
(8,777) |
184,911 |
|
- |
|
| Young Jonathan |
Chief Operating Officer |
• – – |
2023-01-03 |
4 |
OE |
$0.62 |
$5,398 |
D/D |
8,777 |
193,688 |
|
- |
|
| Rolph Timothy |
Chief Scientific Officer |
• – – |
2022-12-29 |
4 |
AS |
$50.55 |
$1,037,119 |
D/D |
(20,316) |
190,532 |
|
- |
|
| Rolph Timothy |
Chief Scientific Officer |
• – – |
2022-12-29 |
4 |
OE |
$28.35 |
$221,584 |
D/D |
7,816 |
210,848 |
|
- |
|
303 Records found
|
|
Page 4 of 13 |
|
|
